spacer
home > ebr > summer 2003 > are patents the beating heart of your boardroom?
PUBLICATIONS
European Biopharmaceutical Review

Are Patents the Beating Heart of your Boardroom?

Most companies do not yet understand that intellectual property (IP) is a lifeline in the brutally competitive world we now face. If you don't believe me here is a quick and easy way to determine the level of IP knowledge in your organisation.

Ask around your colleagues, or even better your boardroom, this simple question: how many years can a court enforce your patents, copyright and trademarks upon other companies?


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee

Ian Harvey is the CEO of BTG, a global technology commercialisation company. He is also Chairman of both the Intellectual Property Institute and the DTI's Intellectual Property Advisory Committee. He joined BTG in 1985 as Chief Executive having spent 10 years with Vickers and Laporte Industries and seven years with the World Bank. Between 1988 and 1993 he served as a member of the Prime Minister's Advisory Council on Science and Technology.

Ian is a Fellow of Nottingham University (1994), and a Member of the Advisory Panel for Science and Technology Policy Research of Sussex University (SPRU) since 1989. He has an MA in Mechanical Sciences from Cambridge University and an MBA from Harvard University.

spacer
Ian Harvey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement